following a full submission:
golimumab (Simponi®) is accepted for use within NHS Scotland.
Indication under review: treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).
Golimumab, compared to placebo, significantly improved symptoms in adults with active non-radiographic axial spondyloarthritis.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of golimumab. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice240KB (PDF)
Medicine details
- Medicine name:
- golimumab (Simponi)
- SMC ID:
- 1124/16
- Indication:
- for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).
- Pharmaceutical company
- MSD
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 February 2016